Accordingly, PI3K inhibition by Alpelisib induces hyperglycemia and marked insulin resistance in more than 50% of patients treated with this drug; these conditions constitute the most frequent adverse event in Alpelisib treatment [5–8]. The gene discussed is PIK3CA; the disease is Hyperglycemia.